Results 111 to 120 of about 8,764 (168)
Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies. [PDF]
Adv TherNovella A +8 more
europepmc +1 more source
Progressive Visual Field Loss in the Setting of Severe Orbital Fat Atrophy. [PDF]
CureusKitsos-Kalyvianakis K +4 more
europepmc +1 more source
Structural and Pharmacological Insights into Propranolol: An Integrated Crystallographic Perspective. [PDF]
Int J Mol SciWitczyńska A +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs & Aging, 2006
Travoprost 0.004%/timolol 0.5% fixed combination (travoprost/timolol) is a once-daily eyedrops solution comprising the prostaglandin F(2alpha) analogue travoprost and the beta-adrenoceptor antagonist timolol. It is indicated for the treatment of patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta ...
Sheridan M, Hoy +2 more
openaire +2 more sources
Travoprost 0.004%/timolol 0.5% fixed combination (travoprost/timolol) is a once-daily eyedrops solution comprising the prostaglandin F(2alpha) analogue travoprost and the beta-adrenoceptor antagonist timolol. It is indicated for the treatment of patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta ...
Sheridan M, Hoy +2 more
openaire +2 more sources
2007
Timolol is a non-selective, beta adrenoceptor antagonist at beta-1 and beta-2 adrenoceptors. It lacks the partial agonist and local anesthetic properties that some drugs in this class have. It is most commonly used to treat glaucoma and cardiovascular diseases. Timolol is moderately lipophilic. Absorption of timolol after topical application to the eye
openaire +2 more sources
Timolol is a non-selective, beta adrenoceptor antagonist at beta-1 and beta-2 adrenoceptors. It lacks the partial agonist and local anesthetic properties that some drugs in this class have. It is most commonly used to treat glaucoma and cardiovascular diseases. Timolol is moderately lipophilic. Absorption of timolol after topical application to the eye
openaire +2 more sources
Archives of Ophthalmology, 1981
To the Editor. —There is increasing evidence of systemic side effects secondary to topical ocular administration of timolol maleate for the treatment of glaucoma. 1,2 These systemic side effects are essentially the same as those seen from systemically administered β-blockers.
E M, Van Buskirk, F T, Fraunfelder
openaire +2 more sources
To the Editor. —There is increasing evidence of systemic side effects secondary to topical ocular administration of timolol maleate for the treatment of glaucoma. 1,2 These systemic side effects are essentially the same as those seen from systemically administered β-blockers.
E M, Van Buskirk, F T, Fraunfelder
openaire +2 more sources